Pernix Therapeutics (PTX)
Pernix Therapeutics Revenue Growth: 43.46%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PTX Revenue Growth Rankings
| Overall | 90th percentile | 415 of 4363 |
| Sector | 83rd percentile | 76 of 457 in Healthcare |
| Industry | 83rd percentile | 6 of 37 in Drug Manufacturers - Other |
PTX Revenue Growth Range, Past 5 Years
| Minimum | 13.77% | Mar 2011 |
| Maximum | 176.4% | Jun 2011 |
| Average | 72.60% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these PTX related companies
PTX News
Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Tough Q1, But Thesis Remains Intact
May 16, 9:20AM Street Insider
May 16, 9:20AM Street Insider
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Upside Scenarios Outweigh Downside Risks
May 16, 8:29AM Street Insider
May 16, 8:29AM Street Insider
Pernix Therapeutics Introduces Omeclamox-PakĀ®, First Product in Gastroenterology Portfolio
May 15, 8:15AM PR Newswire
May 15, 8:15AM PR Newswire
Pernix Therapeutics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 09, 10:43AM Business Wire
May 09, 10:43AM Business Wire
Pernix Therapeutics to Report First Quarter 2012 Financial Results on May 15, 2012
May 07, 10:26AM Business Wire
May 07, 10:26AM Business Wire
$PTX forms bearish "Descending Continuation Triangle" chart pattern. http://stks.co/3TPn
about 38 days ago by RecogniaEvents
about 38 days ago by RecogniaEvents
Canaccord Genuity reiterates a 'Buy' on Pernix Therapeutics (PTX); Unique Small-Cap with Expected Strong Yield
Apr 09, 10:30AM Street Insider
Apr 09, 10:30AM Street Insider
Cantor Fitzgerald Raises Price Target on Pernix Therapeutics (PTX) After Positive Management Meeting
Apr 05, 7:14AM Street Insider
Apr 05, 7:14AM Street Insider
Pernix Therapeutics to Present at the 11th Annual Needham Healthcare Conference
Mar 29, 12:15PM Business Wire
Mar 29, 12:15PM Business Wire
Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Solid Q4, Execution & Business Development The Focus
Mar 29, 8:38AM Street Insider
Mar 29, 8:38AM Street Insider
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Adjusting Estimates After Q4 Results
Mar 29, 8:15AM Street Insider
Mar 29, 8:15AM Street Insider
Pernix Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 28, 8:00AM Business Wire
Mar 28, 8:00AM Business Wire
$PTX forms bullish "Continuation Diamond" chart pattern. http://stks.co/36kB
about 65 days ago by RecogniaEvents
about 65 days ago by RecogniaEvents
Pernix Therapeutics to Report Fourth Quarter and Full Year 2011 Financial Results on March 28, 2012
Mar 20, 9:30AM Business Wire
Mar 20, 9:30AM Business Wire
Needham & Company Maintains a 'Buy' on Pernix Therapeutics (PTX); Continues Winning Top Line Ways
Mar 08, 7:54AM Street Insider
Mar 08, 7:54AM Street Insider
Pernix Therapeutics Provides Business Update and Announces New Product Development Agreement
Mar 07, 8:31AM Benzinga
Mar 07, 8:31AM Benzinga
Pernix Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 28, 10:39AM Business Wire
Feb 28, 10:39AM Business Wire
Pernix Therapeutics (PTX) Enters Licensing Agreement for Gastroenterology Treatment
Jan 23, 8:37AM Street Insider
Jan 23, 8:37AM Street Insider
Pernix Therapeutics (PTX) Enters Agreement to License New FDA-Approved Product to Treat Gastroenterology Disease in U.S.
Jan 23, 8:37AM Street Insider
Jan 23, 8:37AM Street Insider
Cantor Fitzgerald Starts Pernix Therapeutics (PTX) at Buy, Stocks Undervalued Based on Pipeline Outlook
Dec 21, 4:49PM Street Insider
Dec 21, 4:49PM Street Insider
Pernix Therapeutics Expands Senior Management Team to Support Continued Business Growth
Dec 06, 9:00AM Business Wire
Dec 06, 9:00AM Business Wire
Pernix Therapeutics to Present at the Piper Jaffray 23rd Annual Health Care Conference
Nov 21, 3:30PM Business Wire
Nov 21, 3:30PM Business Wire
my largest positions remain $GYRO, $PTX and $NEM. PTX reports next week. I expect good news on their newest product, Natroba.
about 203 days ago by brianjroach
about 203 days ago by brianjroach
$PTX The company presented well at the Stifel Nicolaus Healthcare conference on Wednesday. EPS growth looks solid for several Qs.
about 267 days ago by brianjroach
about 267 days ago by brianjroach
$PTX shares were sold in a registered offering pursuant to an underwriting agreement executed on July 21, 2011
about 310 days ago by canarionyc
about 310 days ago by canarionyc
$PTX $8.59 Collins Cooper C. 10% owner (President and CEO) S 498,429 @ $7.00 amnt $3,489,000 own'd 8,906,570 proc'd ($792,502) 7/21/2011
about 310 days ago by canarionyc
about 310 days ago by canarionyc
$PTX $8.59 Smith James Edward Jr. director 10% owner S 280,047 @ $7.00 amnt $1,960,330 own'd 4,992,700 proc'd ($445,275) 7/21/2011
about 310 days ago by canarionyc
about 310 days ago by canarionyc
$PTX http://chart.ly/xiwr86n Biotech, for you thin-addicts out there.. Ready to roar, not aware of any catalysts..
about 394 days ago by abtrader
about 394 days ago by abtrader
$PTX http://chart.ly/5xajtdi PTX - 40% Barchart.com sell signal-21.89% off high-Relative Strength Index 40.74% and falling
about 442 days ago by jimvanmeerten
about 442 days ago by jimvanmeerten
$PTX http://chart.ly/ymyvos7 Didn't get involved in this one due to concerns over the volume, but there she goes!
about 471 days ago by fornix
about 471 days ago by fornix
$PTX http://chart.ly/b3pe42e This one could be good over $11.15s. On my watchlist. Would like to see more volume
about 472 days ago by fornix
about 472 days ago by fornix
RT @OptionRadar: $PTX - Pernix up more than 50% since my post 7 days ago: http://stk.ly/eJ1uyP
about 494 days ago by powitz
about 494 days ago by powitz
$PTX - Pernix up more than 50% since my post 7 days ago: http://stk.ly/eJ1uyP
about 494 days ago by OptionRadar
about 494 days ago by OptionRadar
$PTX http://chart.ly/dtc36ou Pernix Therapeutics - Interesting Drug Maker (Zema-Paks) - Momentum
about 501 days ago by OptionRadar
about 501 days ago by OptionRadar
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PTX | 6.59 | -0.47 | -6.66% | 181.72M |
| PTSX | 0.57 | +0.00 | +0.00% | 5.991M |
| PTRY | 12.89 | -0.03 | -0.23% | 300.52M |
| PTR | 125.99 | +0.34 | +0.27% | 229.94B |
| PRU | 46.45 | -0.20 | -0.43% | 21.92B |
| PRTS | 4.11 | +0.10 | +2.49% | 122.91M |
| PRST | 0.5401 | -0.04 | -6.88% | 21.68M |
| PRSC | 13.31 | +0.10 | +0.76% | 171.86M |
| PPLT | 139.54 | +1.32 | +0.95% | |
| PPL | 27.37 | +0.08 | +0.29% | 15.81B |